ViaSlim

Prescriber, not dispenser. ViaSlim runs the clinical front end from Zürich and Bern; MediService AG (Redcare-owned, Zuchwil SO) dispenses, and the patient contracts with MediService, not ViaSlim, for the medicine under AGB 4.5. Redcare Apotheke Schweiz is a third leg, sending traffic through its own Online-Arzt-Service Adipositas.

Two tracks: a CHF 0 insurance track requiring an on-site Zurich consultation, which covers consultations and dietetics but not the medication; and a self-pay track. Six languages in the funnel, four on the site, in a market where nobody serves Romandie or Ticino natively.

No holding company, no foreign parent, no subsidiary. Founders Dr. Gezim Dervishi and Norbert Niebuhr each hold sole signature; Dr. Adel Abdel-Latif, a non-physician consultant domiciled in Dubai, joined the board on 15 July 2025 with restricted joint-two signature and no accompanying capital event.

The Bern branch sits inside Prof. Dr. Jörg Zehetner’s Swiss1Chirurgie AG, whose Klinik Beau Site is a SMOB-recognised bariatric Referenzzentrum. That link was created eleven months before the BAG published criteria requiring exactly it, and it is the best-constructed piece of the model.

Three self-pay prices live simultaneously in three systems: CHF 225 on every marketing page, CHF 299 at the actual checkout, and CHF 499 for the tirzepatide tier the marketing site never mentions. Billing is every 28 days, so 13 periods a year, giving CHF 3,887 or CHF 6,487 annually. The CHF 0 track still costs the patient franchise plus 10% Selbstbehalt, which ViaSlim’s own blog puts at CHF 1,000 to 3,200 a year.

No priced equity round has ever closed. Across all six SHAB publications since incorporation there is not one Kapitalerhöhung: share capital has been CHF 100,000 unchanged since 29 April 2024. The Revisionsstelle was waived at incorporation, so there are no audited accounts and no filing obligation. The only public statement is bootstrap funding plus an unnamed angel investor specialising in obesity, with a pre-seed “planned” as of March 2025. Not on Innosuisse, not in any startup database.

Self-reported and internally inconsistent: 1,131+ registrations on the Redcare-facing page against 3,000+ on the membership page, plus 5,000+ consultations and 2,000+ GLP-1 courses. Trustpilot has 38 reviews, clustered October to November 2025. Headcount undisclosed; eleven people are named.

One genuinely candid disclosure: an internal retrospective cohort, n = 358 with an ethics vote, reporting minus 13.1% at 20 weeks at a median dose of 1.3mg against the 2.4mg STEP-1 target. It sits behind the referrer gate where no patient sees it.

No Swissmedic action naming ViaSlim was found, but Swissmedic does not publish most advertising interventions and its posture is the most aggressive in Europe: in January 2025 it ordered Blick, NZZ and 20 Minuten to delete GLP-1 journalism.

Against that standard ViaSlim is materially exposed by its own published content: an indexed public dose-per-click calculator naming Semaglutid and Tirzepatid, 88 blog posts naming Wegovy 176 times, and an ungated “Wegovy vs. Mounjaro” comparison inside its own funnel.

The bigger question is the March 2026 BAG obesity-centre recognition framework, which turns ViaSlim’s self-declared “erstes hybrides Adipositaszentrum der Schweiz” into something a SMOB and SGED committee must grant. It has no endocrinologist on the roster.

Across all six SHAB publications since incorporation there is not one Kapitalerhöhung, not one Statutenänderung touching capital, and not one new shareholder event. Share capital has been CHF 100,000 fully paid, unchanged, from 29 April 2024 to today.

So no priced equity round has ever closed into the cap table. Whatever money has arrived came as founder capital, convertible loan, SAFE-equivalent, revenue or shareholder loan, none of which touch the register. Combined with the Revisionsstelle opt-out, there are no audited accounts and no filing obligation: revenue, burn and headcount are unobtainable from any public Swiss source.

The only substantive public statement is Startupticker’s launch piece of 27 March 2025: bootstrap financing by the founders, initial funding from an unnamed angel investor specialising in obesity treatment, and a Pre-Seed round being planned. No round has been announced since. Nothing on Crunchbase, Dealroom, EU-Startups or the Swiss Startup Radar. Not on the Innosuisse list of approved start-up innovation projects. No Venturelab, no accelerator, no grant.

The Abdel-Latif appointment on 15 July 2025 was not accompanied by any capital event. Given his profile, a consultant with his own AG, domiciled in Dubai, appointed with restricted joint-two signature while both founders keep sole signature, it reads more like a governance or investor-representation seat than a control transaction. The domicile move three weeks later, out of shared practice infrastructure into ViaSlim’s own Zurich address, is consistent with a funding event but nothing corroborates it.

ViaSlim publishes different figures on different pages simultaneously:

| Metric | Value | Page | |---|---|---| | Patientenanmeldungen | 1,131+ | /redcare | | Patientenanmeldungen | 3,000+ | /membership | | Konsultationen im ersten Jahr | 5,000+ | /about-us, /zuweiser | | Begleitete GLP-1-Verläufe | über 2,000 | /zuweiser |

The Redcare-facing landing page, the one a distribution partner sends traffic to, is running the stale number. Use 3,000+ registrations and 5,000+ consultations as the current self-reported scale.

Headcount is not disclosed. The about-us page names eleven people, six physicians, four nutrition professionals and one care manager. That is a floor, not a headcount.

ViaSlim publishes an internal retrospective cohort, ViaSlim RWE-01, n = 358, with an ethics vote and a manuscript submitted for publication. It reports −13.1% weight loss in completers at 20 weeks or more, at a median dose of 1.3mg semaglutide against the 2.4mg STEP-1 target, with the caveat that it is not a registered trial and may not generalise.

Publishing a below-trial result, and disclosing that the median patient never titrates to the licensed weight-management dose, is candid in a way nothing else in this atlas is. It is their strongest credibility asset.

It is also commercially revealing, and it appears only on the referrer-facing page, where no patient will see it.

It does hold on the German homepage, /female, /male, /why-viaslim, /about-us and their translations, which use only euphemism: modernste Medikamente, ärztlich verschriebene Wirkstoffe, Originalmedikament. The JSON-LD is clean, a MedicalClinic graph with no Offer and no drug names.

It breaks in six places, none of them gated:

| Location | What is exposed | |---|---| | Homepage feature grid | “Moderne Medikamente / GLP-1-Medikamente bei medizinischer Indikation” | | `/klick-rechner` | A public, sitemap-listed, indexable dose-conversion tool for prescription injectables, naming Semaglutid and Tirzepatid, with pen strengths and a click-per-dose reference table | | /zuweiser | “Medikamentöse Therapie nach Leitlinie Semaglutid, Tirzepatid”, with quantified efficacy of ~21% and ~15% | | 88 German blog posts | Wegovy 176 mentions, Semaglutid 586, Ozempic 88, Tirzepatid 34 | | /sunday meta description | “Evidenzbasierte Nahrungsergänzungsmittel für deine GLP-1-Therapie” | | The onboarding funnel bundle | Mounjaro 130 times, Ozempic 12 times |

Mounjaro appears zero times on the website and 130 times in the funnel bundle.

The klick-rechner page also ships unreplaced Webflow boilerplate live and submitted to Google: “Eyebrow Text Here”, “Lorem ipsum dolor sit amet elit”, “Button Text”.

Decoded from the public onboarding bundle. The German strings are compiled straight into it:

• programLanding.compare.title = “Wegovy vs. Mounjaro”
• compare.wegovyLoss = “17 %”, mounjaroLoss = “22 %”
• compare.wegovySpecial = “Senkt nachweislich das Risiko für Herz-Kreislauf-Ereignisse”
• compare.rowPrice = “Preis pro Monat”, rendered per brand
• quizLayout.sidebar.description = “Fragst du dich, ob deine Versicherung Medikamente wie Ozempic® oder Wegovy® abdeckt?”

The same strings exist in six languages including Albanian and Spanish. And the router’s _authenticated guard covers only the dashboard and appointment routes: `/program-medication`, `/program-duration`, `/plan-summary` and `/results` are unauthenticated. The branded product imagery is served openly with no cookie and no auth header, at up to 377KB per file.

Assessment. ViaSlim has not chosen a different regulatory posture from DoktorABC or Apomeds. It has chosen a different placement: brand names moved off the Webflow marketing shell and into the blog, which is not gated, and into an SPA one subdomain over, which is also not gated. The euphemism on the homepage buys very little when viaslim.ch/klick-rechner publishes a click-per-milligram dosing table.

Swissmedic’s posture on art. 31 and 32 HMG is the most aggressive in Europe. In January 2025 it sent cease-and-desist letters under penalty to Blick, NZZ and 20 Minuten demanding deletion of editorial articles about weight-loss injections, on the reasoning that even mere information about medication uses constitutes advertising if it is designed and suitable to influence consumer behaviour.

Against that standard, ViaSlim’s public content is materially more exposed than the journalism Swissmedic went after. Three specifics:

• The /zuweiser page names both molecules with quantified efficacy and is reachable by anyone. The only barrier is a self-declaration button, “Ja, ich bin medizinische Fachperson”. Swissmedic has consistently treated unverified self-declaration gates as insufficient to convert Publikumswerbung into Fachwerbung.
• That same page states “Zulassungsstatus und mögliche Off-Label-Anwendungen werden im Einzelfall geprüft” while presenting Tirzepatide, which is not on the Spezialitätenliste for weight reduction in Switzerland. Publicly framing an off-label pathway is a distinct additional risk.
• The consumer blog carries roughly 60 posts on GLP-1 pharmacology, dosing, side effects and discontinuation, plus posts naming Swissmedic and specific insurers. This is exactly the category of content Swissmedic ordered deleted from national newspapers.

No Swissmedic action naming ViaSlim was found. But this is the highest-probability enforcement vector in the file, higher than the licensing question, and it is entirely self-inflicted through published content.

What Redcare says about ViaSlim: its Online-Arzt-Service Adipositas page describes a three-step telemedicine flow, links out with “Termin online anfragen” to viaslim.ch/de/redcare, and names MediService as the fulfilment arm with free shipping in one to two days. It names no prices and no medicines, so Redcare is running the discipline ViaSlim only pretends to.

What ViaSlim says about Redcare: essentially nothing. The word “RedCare” appears in exactly two places on viaslim.ch/redcare, the <title> and the og:title. The rendered body has zero Redcare branding, no logo, no partnership explanation and no mention of MediService. It is a byte-for-byte stale clone of an older ViaSlim homepage, still showing “Jetzt auch in Zürich vor Ort” with no Bern and no Basel, the outdated 1,131 patient count, the broken ratings block, and the CHF 225 price the checkout will not honour.

A distribution partner is sending traffic to a page that misstates the locations, the scale, the rating and the price.

MediService is named by ViaSlim in three low-visibility places only, never in marketing: the Datenschutzerklärung (with a typo, “Medikamentenliferung”), AGB 4.5 (“Im Rahmen der Medikamentenbestellung treten Sie in eine Geschäftsbeziehung mit der MediService AG”), and one customer testimonial.

One trap. ViaSlim links to booking.mymediservice.ch/viaslim/. Despite the domain, this is not MediService AG. Its Impressum names MEDISYN SA in Lucerne; it is the blood-draw booking system, listing 11 phlebotomy sites, not the 12 Startupticker reported. Anyone reading the domain alone will wrongly conclude they have proven the MediService link.

88 German posts, 134 blog URLs. German-only for anything commercial.

Themes: GLP-1 clinical management (~30 posts on side effects, titration, discontinuation, muscle preservation); reimbursement and cost (~10, the highest commercial intent); competitor comparison (4); safety and counter-positioning (~6).

The programmatic seam is named insurers. Helsana, SWICA and CSS each get a targeted post. Concordia, Sanitas, Visana and Groupe Mutuel are unclaimed, which is the obvious expansion.

There are also four competitor comparison posts: viaslim-vs-weight-doctors, viaslim-vs-ovivamed-vs-everyman-health, schweizer-abnehm-anbieter-vergleich-2026, and a “how to choose a clinic” piece framed as seven neutral test questions. Note that two of those competitors, Weight Doctors and Everyman Health, did not surface in the market sweep and should be added to the Switzerland page.

And one post is a Faktencheck of Swiss media coverage of GLP-1 side effects, which is a bold thing to publish in the jurisdiction where the regulator has been ordering newspapers to delete GLP-1 articles.

Webflow behind Cloudflare, with the preload CSS still named `viaslim-staging.webflow.shared…min.css`, a staging asset name in production. The funnel is a separate SPA on onboarding.viaslim.ch.

What is publicly readable without authentication: all copy and pricing in six languages compiled into one JS bundle, the complete route table, branded product imagery, a hardcoded i18n API key, lorem-ipsum pages in the production sitemap, and internal competitive-intelligence report slugs published with dates.

Anyone can diff ViaSlim’s pricing weekly by re-fetching a single JS file. For a competitor, that is the cheapest monitoring setup in this atlas.

The Impressum is also defective. It states “Eingetragen im Handelsregister des Kantons Zürich: CH-036.9.099.949-7”. That CHID is the Bern branch, registered in Bern. The Zurich AG’s CHID is CH-020.3.054.276-9. No UID is given anywhere, no named responsible person, no medical director, no supervisory authority. Art. 3 Abs. 1 lit. s UWG requires clear identification of the supplier; this is a low-cost complaint for a competitor or SECO. The nav also carries a “Kosten” link that returns Page Not Found.

Trustpilot: 38 reviews, clustered 26 October to 29 November 2025. Trustpilot returned 403 to every fetch, so the score is secondary. ViaSlim’s own pages claim 5.0 on the homepage, 4.8 on selbsttest.viaslim.ch, and a mislabelled “5.0 / 4.8” on /redcare. The balance of its own evidence points to 4.8, and the homepage 5.0 should be treated as unreliable.

A Trustpilot Zurich location sub-profile exists, which indicates a claimed and location-verified business profile.

Google review counts for the Zurich and Bern practices could not be retrieved and are flagged as a gap rather than guessed. A Places API lookup on the two linked place IDs would close it in minutes.

No Swiss press coverage was found, despite a “Bekannt aus den Medien” logo strip with no article links, no publication names in text and no dates.

The referrer page publishes ViaSlim RWE-01: n = 358, ethics vote obtained, manuscript submitted, reporting −13.1% weight loss in completers at 20 weeks or more, at a median dose of 1.3mg against the 2.4mg STEP-1 target, with the caveat that it is not a registered trial and may not generalise.

A company publishing a result below the trial benchmark, and disclosing that most of its patients never reach the licensed dose, is doing something none of the UK operators in this atlas do. It is their best asset.

It is behind the self-declaration gate, on a page aimed at referring physicians, where no patient will ever see it.